In today's Pharmaceutical Executive Daily, Senate Democrats press major pharmaceutical companies for transparency on the ...

In 2025 it seemed the only certainty for biotech was more uncertainty. Biotech leaders conducted business as usual against ...

FDA now permits Arexvy for adults 18–49 with elevated RSV risk from conditions such as chronic cardiopulmonary or renal disease, obesity, and diabetes. Epidemiology in U.S. adults 18–49 includes ...

For Andrew Hall, a veteran of Big Pharma-turned biotech builder, he has spent much of his recent career operating inside those constraints — and learning how to lead through them. Today, as CEO of ...

Poor/fair health status correlated with greater cost-related trade-offs, indicating those with higher healthcare utilization are simultaneously more exposed to affordability-driven nonadherence and ...

In today's Pharmaceutical Executive Daily, a new West Health-Gallup survey finds that more than 82 million Americans have cut back on daily expenses to cover healthcare costs, the FDA expands the ...

Testing identified significant impurity formation when tirzepatide is compounded with B12 variants, suggesting chemical incompatibility that is not evaluated under FDA review pathways. Uncertainty ...

In today’s Pharmaceutical Executive Daily, Vinay Prasad exits the FDA’s Center for Biologics Evaluation and Research for the ...

While regulatory alignment remains essential, operational urgency driving companies to AI adoption is equally profound. In ...

The second exit in under a year follows controversy around CRLs for Replimune and Capricor, including criticism that mid- and ...

In a conversation with Pharmaceutical Executive Ron Lanton, Senior Partner & Global Strategist, Lanton, Lanton & Sosa Law ...

Market access strategies are evolving as more biopharma companies commercialize their own therapies, requiring closer ...